Evidence map›Paper›PMID 36345477›Full record

ArticleComputational and mathematical methods in medicine2022

In Silico and In Vitro Studies on the Mechanisms of Chinese Medicine Formula (Yiqi Jianpi Jiedu Formula) in the Treatment of Hepatocellular Carcinoma.

Zhulin Wu, Jianyuan Kang, Wanjun Tan, Chunshan Wei, Li He, Xiaoyan Jiang, Lisheng Peng

Open access · hybridAbstract read
In one paragraph

Article in Computational and mathematical methods in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. A review ofFrontiers in pharmacology · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zhulin WuThe Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, China.ORCID https://orcid.org/0000-0002-7727-0119
Jianyuan KangThe Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, China.
Wanjun TanShenzhen Futian Center for Chronic Disease Control, Shenzhen 518033, China.
Chunshan WeiThe Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, China.ORCID https://orcid.org/0000-0002-3960-4069
Li HeThe Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, China.ORCID https://orcid.org/0000-0001-6381-7155
Xiaoyan JiangThe Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, China.
Lisheng PengThe Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, China.ORCID https://orcid.org/0000-0002-5530-1738
Guangzhou University of Chinese Medicine · CNShenzhen Nanshan Center for Chronic Disease Control · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Traditional Chinese medicine (TCM) is an important part of the comprehensive treatment of hepatocellular carcinoma (HCC), and Chinese materia medica formulas with the effect of "Yiqi Jianpi" (replenishing qi and strengthening spleen) or "Jiedu" (removing toxicity) have been proved to be effective in treating HCC. However, mechanisms of these formulas in treating HCC remain unclear. In this paper, our goal is to explore the antitumor activity and its molecular mechanisms of Yiqi Jianpi Jiedu (YQJPJD) formula against HCC. Methods: The bioactive ingredients and targets of YQJPJD formula and HCC targets were screened by five Chinese materia medicas and two disease databases, respectively. The network pharmacology was utilized to construct the relationship network between YQJPJD formula and HCC, and the mechanisms were predicted by the protein-protein interaction (PPI) network, pathway enrichment analysis, bioinformatics, and molecular docking. Numerous in vitro assays were performed to verify the effect of YQJPJD formula on HCC cells, cancer-associated targets, and PI3K/Akt pathway. Results: The network relationship between YQJPJD formula and HCC suggested that YQJPJD formula mainly regulated the potential therapeutic targets of HCC by several key bioactive ingredients (e.g., quercetin, luteolin, baicalein, and wogonin). PPI network, bioinformatics, and molecular docking analyses displayed that YQJPJD formula may play an anti-HCC effect through key targets such as MAPK3, RAC1, and RHOA. Additionally, pathway analysis demonstrated that YQJPJD formula could play an anti-HCC effect via multiple pathways (e.g., PI3K-Akt and hepatitis B). Experimental results showed that YQJPJD formula could effectively inhibit the proliferation, migration, and invasion of HCC cells and promote HCC cell apoptosis in a concentration-dependent manner. Moreover, YQJPJD formula could decrease the mRNA expression of Conclusion: YQJPJD formula mainly exerts its anti-HCC effect through multiple bioactive ingredients represented by quercetin, as well as multiple pathways and targets represented by PI3K/Akt pathway,

Indexed as

Carcinoma, HepatocellularDrugs, Chinese HerbalLiver Neoplasmsbeta CateninHumansMedicine, Chinese TraditionalMolecular Docking SimulationPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktQuercetinbeta CateninDrugs, Chinese Herbaljianpi jieduPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktQuercetin

Identifiers

PMID36345477
PMCPMC9637043
OpenAlexW4307810509

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.